Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Unknown 1Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Neoplasms 2875Carcinoma, Non-Small-Cell Lung 2428Breast Neoplasms 2068Colorectal Neoplasms 1247Neoplasm Metastasis 1232Prostatic Neoplasms 1080Melanoma 974Multiple Myeloma 963Ovarian Neoplasms 904Recurrence 852Leukemia, Myeloid, Acute 810Lung Neoplasms 758Pancreatic Neoplasms 753Lymphoma, Non-Hodgkin 727Lymphoma 660Stomach Neoplasms 623Carcinoma, Hepatocellular 566Carcinoma, Renal Cell 546Squamous Cell Carcinoma of Head and Neck 529Leukemia, Lymphocytic, Chronic, B-Cell 493Lymphoma, Follicular 468Head and Neck Neoplasms 451Glioblastoma 436Advanced Solid Tumors 432Small Cell Lung Carcinoma 411Triple Negative Breast Neoplasms 410Lymphoma, Large B-Cell, Diffuse 398Leukemia 394Uterine Cervical Neoplasms 369Advanced Solid Tumor 351

Interventions

Capecitabine 2Vinorelbine 1Trastuzumab 1Lapatinib 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × HER2-positive Advanced Breast Cancer × Clear all
NCT07047365 2026-06-03

TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Recruiting
416 enrolled
Breast

HER2-positive Advanced Breast Cancer

NCT05901935 2023-06-13

DP303c in Patients With HER2-positive Advanced Breast Cancer

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 3 Not yet recruiting
420 enrolled
Breast

HER2-positive Advanced Breast Cancer

NCT04185649 2019-12-04

The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer

Bio-Thera Solutions

Phase 3 Unknown
410 enrolled
Breast

HER2-positive Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡